phospho-C-Myc (Ser373) Polyclonal Antibody, PE Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-8442R-PE |
| Product Name | phospho-C-Myc (Ser373) Polyclonal Antibody, PE Conjugated |
| Applications |
WB
FCM
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat, Cow, Pig |
| Specifications | |
| Conjugation | PE |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human C-Myc around the phosphorylation site of Ser373 |
| Modification Site | Thr373 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4609 |
| Subcellular location | Nucleus |
| Synonyms | MycSer373; MycS373; p-MycSer373; p-MycS373; AU016757; Avian myelocytomatosis viral oncogene homolog; bHLHe39; c Myc; Cellular myelocytomatosis oncogene; |
| Background | The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. [provided by RefSeq, Jul 2008]. |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |